




RealRate

PHARMACEUTICAL 2021

Adamas Pharmaceuticals Inc
Rank 250 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

Adamas Pharmaceuticals Inc Rank 250 of 409

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 148% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is -199%, being 156% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	111,736
Cost of Goods Sold	2,038
Intangible Assets	0
Liabilities, Current	34,867
Liabilities, Non-Current	135,138
Other Assets	6,695
Other Compr. Net Income	-16
Other Expenses	13,239
Other Liabilities	0
Other Net Income	0
Property and Equipment	1,598
Research and Development	9,746
Revenues	74,461
Selling, General and Administrative Expense	106,841

Output Variable	Value in 1000 USD
Assets	120,029
Liabilities	170,005
Expenses	131,864
Stockholders Equity	-49,976
Net Income	-57,403
Comprehensive Net Income	-57,411
Economic Capital Ratio	-199%

